RET and non-small cell lung carcinoma: In NSCLC with RET mutations, partial responses have been reported but clinical benefit has been limited and these agents have not to date significantly improved patient outcomes (Drilon et al., 2016; Gautschi et al., 2017; Yoh et al., 2017; Ferrara et al., 2018).